ALNY— AI Stock Forecast & Price Targets
Published 8/10/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live ALNY price forecast →
ALNY's fundamental strength from its TTR franchise and pipeline optionality remains intact despite recent repricing, but technicals show a broken base with significant downside risk to $197.81. The stock is currently trading at a deep discount to historical highs while facing elevated short interest and bearish analyst sentiment.
Wait for confirmation above $235 to validate a base; if price breaks below $200, consider shorting with stop-loss at $219.20. Invalidation level is $273 (previous support).
Hold until Q3 2026 earnings confirm stabilization of ATTR-CM demand. Target return range: 5-15% over 6 months if the stock holds above $235. Catalysts include Phase 3 trial results and competitive data on acoramidis.
Long-term thesis hinges on pipeline execution, particularly ALN-6400 Phase 1 readout in H2 2026 and TTR franchise growth. Structural risk is competitive pressure from next-gen modalities; if the company can maintain market share, long-term upside could reach $350+ by 2028.
Revenue growth remains robust with Q2 2026 revenue at $1.29B (+74% YoY) and TTR franchise generating over $1B quarterly. Margins are strong (gross margin 79.65%, operating margin 20.81%) with high ROE (~100%). Cash flow is healthy ($292M FCF in Q2), but debt-to-equity ratio of 220.623 indicates significant leverage. The balance sheet shows strong liquidity (current ratio 3.05) and cash reserves ($3.3B total cash). However, the $2B Inceptive AI commitment strains near-term cash flow, and competitive pressure from next-gen modalities like acoramidis poses a threat to market share.
The chart shows a broken base with price trading below the 52-week low of $197.81. The green line (actual) is trending downward against the yellow forecast band, which suggests continued downside pressure. Key support levels are at $200-$235, but the stock has failed to hold these areas. The SMA20 (-14.35%) and SMA50 (-21.84%) indicate weak momentum, while RSI (34.20) suggests oversold conditions but not yet a reversal signal. The forecast band shows a potential downside to $219.20 with no clear upside breakout above the current price.
Recent news highlights TTR franchise success ($1B+ quarterly revenue in Q2 2026) and pipeline progress, including Phase 3 trials for Nucresiran and Zilebesiran. However, Truist Financial cut its target to $315 from $410, signaling bearish sentiment. The stock is also facing competitive pressure from next-gen modalities like acoramidis, which could compress market share. While social sentiment is overwhelmingly bullish (100% bullish on StockTwits), the technicals and analyst consensus suggest a lack of near-term upside.
- ALN-6400 Phase 1 readout in H2 2026 for obesity and weight management
- TTR franchise revenue growth to $1.5B+ annually by 2027
- Competitive pressure from acoramidis compressing second-line ATTR-CM market share
- Elevated short interest (4.33%) and bearish analyst sentiment
- Q3 2026 earnings may confirm further TTR guide cuts
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord